Literature DB >> 11350051

Diminution of phagocytosed perfluorocarbon emulsions using perfluoroalkylated polyethylene glycol surfactant.

Y C Hsu1, C A Peng.   

Abstract

Perfluorocarbon emulsions have been considered as potential blood substitutes for years due to their high capacity of dissolving respiratory oxygen and carbon dioxide. However, they have been reported to associate with side effects (e.g., flu-like syndrome) after being injected into animal's bloodstream. The cause of these side effects is related to the phagocytosis of perfluorocarbon emulsions by cells (e.g., macrophages). Inspired by the approach of using polyethylene glycol (PEG) to camouflage liposomes, we synthesized a perfluoroalkylated PEG (R(F)-PEG) surfactant to provide steric hindrance for decreasing phagocytosis of perfluorocarbon emulsions. The R(F)-PEG surfactant along with Pluronic F-68 and egg yolk phospholipid mediated perfluorocarbon emulsions were incubated individually with J774A.1 macrophages to examine the degree of phagocytosis. 19F NMR studies were used to quantitatively determine the amount of perfluorocarbon emulsions phagocytosed by macrophages. Results showed that the degree of phagocytosis was diminished to a large extent for perfluorocarbon microparticles emulsified by the R(F)-PEG surfactant. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350051     DOI: 10.1006/bbrc.2001.4862

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Perfluorohexane-loaded macrophages as a novel ultrasound contrast agent: a feasibility study.

Authors:  Liselotte M Kornmann; Daniëlle M J Curfs; Evelien Hermeling; Ingeborg van der Made; Menno P J de Winther; Robert S Reneman; Koen D Reesink; Arnold P G Hoeks
Journal:  Mol Imaging Biol       Date:  2008-06-07       Impact factor: 3.488

2.  Reduced phagocytosis of colloidal carriers using soluble CD47.

Authors:  Yu-Chih Hsu; Marcela Acuña; Stanley M Tahara; Ching-An Peng
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.